Novartis gets EU nod for Jakavi cancer drug; Sun's Caraco gets FDA clearance for U.S. plants;

 @FiercePharma: AstraZeneca's gain is Roche's loss: Stock down 1% after $AZN woos away Pascal Soriot for CEO job. More | Follow @FiercePharma

> Novartis ($NVS) won approval from European regulators for its myelofibrosis treatment Jakavi, the first drug approved for the rare blood cancer. Report

> Sun Pharmaceuticals got the go-ahead from FDA to restart manufacturing operations at a U.S. subsidiary's plant and packaging facilties in Detroit and Wixom, MI. Report

> UBS downgraded GlaxoSmithKline ($GSK) to "neutral" from "buy," saying it doesn't expect GSK stock to continue outperforming its peers. Report

> India's Cipla is scouting Mumbai to buy office space for a headquarters relocation, The Economic Times reports. Report

> Express Scripts persuaded a U.S. judge to dismiss most of the antitrust claims lodged against its $29 billion buyout of Medco Health Solutions, by drugstore chains and a pharmacy association. Report

Medical Device News

@FierceMedDev: Moving on from the Duet recall, Covidien gets a 510(k) for its next-gen surgical stapler. News | Follow @FierceMedDev

 @MarkHFierce: Stent use can help certain patients more than medical therapy if used on the early side. Release | Follow @MarkHFierce

 @DamianFierce: Joining other big shots in the device game, Medtronic has opened an R&D center in China. Report | Follow @DamianFierce

> Sequenom expands prenatal diagnostic with overseas deals. Story

> Shake-up at Roche puts Diggelmann in charge of diagnostics. News

Biotech News

 @FierceBiotech: Special report: The Alzheimer's pipeline... What's next? Report | Follow @FierceBiotech

 @JohnCFierce: Resverlogix touts positive PhIIb atherosclerosis data, sets sights on PhIII deal. More | Follow @JohnCFierce

 @RyanMFierce: What changes will Roche vet Pascal Soriot make as CEO of AstraZeneca? More | Follow @RyanMFierce

> Alnylam reaps $29M harvest in new ag bio deal with Monsanto. News

> Analysis: Where will Pascal Soriot take AstraZeneca now? More

> FDA OK for HIV pill Quad sets up potential confrontation over Gilead's price. Article

Biotech Research News

> Acorda's drug treats nerve damage-related ED in preclinical test. Article

> Novira raises $23M for hepatitis B/HIV drug work. News

> Genentech, U. Minnesota scientists discover new colon cancer red flags. Story

> Johns Hopkins team turning blood cells into stem cells. More

> Melanoma stem cells may carry provocative drug target. Item

Pharma Manufacturing News

> Drugmaker EirGen thinks plan to put waste station nearby stinks. More

> Sun says FDA clears plants where Marshalls seized products in 2009. News

> CSL, whose vaccine was tied to convulsions, gets FDA closeout letter. Story

> Hospira commits to 200 jobs, $85M investment, at troubled plant. Report

And Finally... Cancer patients need treatment for emotional and psychological distress, too. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.